 |
|
|
 The Society of Interventional Oncology submitted updates to the NCCN non-small cell lung cancer guidelines. Submitted by Patrick W. Eiken, MD, Professor of Radiology, Mayo Clinic, Florian J. Fintelmann, MD, Assistant Professor of Radiology, Harvard Medical School, Robert D. Suh, MD, Clinical Professor, David Geffen School of Medicine at UCLA. This letter requests updating the role of image-guided thermal ablation (IGTA) in the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC. Download the complete letter here.
 Check out the latest SIO Case Spotlight: Cryoablation of Recurrent Central RCC with Renal Vein Invasion from authors Ahmad Parvinian, MD, Nick Kurup, MD, Tom Atwell, MD at Mayo Clinic.
What is Case Spotlight? The Society of Interventional Oncology presents an opportunity to share key findings from interesting patient cases within the interventional oncology community. Access to these cases and engaging in the discussion surrounding their content is one of the benefits of SIO membership.
The Society of Interventional Oncology (SIO) is pleased to announce the annual SIO Fellow and Resident Scholarship. Apply today to attend the SIO2020 Annual Meeting, network with esteemed IO luminaries from around the world, and participate in the IO Essentials program.
Scholarship Benefits
- Invitation to the IO Essentials Program taking place Thursday, 30 January
- Build a strong foundation for a successful IO career though our scientific program
- Receive high-quality, targeted Interventional Oncology education
- Network with esteemed experts from around the globe
- High-scoring applicants will have their case featured in an SIO2020 session and/or SIO's Case Spotlight
- Special invitation to symposia sponsored by industry leaders such as BTG and Guerbet
- One year of complimentary membership to SIO
Application Requirements
- Current CV
- Letter of recommendation from an Interventional Oncology/Radiology program director or faculty member
- Case submission for SIO2020’s Complex IO Session
- Completed W-9 (only required for US candidates)
Share your science with hundreds of professionals in the global interventional oncology community: Submit an abstract to present at SIO2020, taking place 31 January–3 February 2020 in New Orleans, Louisiana!
 Abstracts due 9 September 2019 at 11:59pm ET.
Accepted abstract authors will be recognized on the Society of Interventional Oncology website and in the SIO mobile app. All accepted abstracts will also be eligible for a scientific award to be presented at SIO2020!
Visit the SIO website to learn more, to submit your abstracts, and to register for the meeting.
Medicina ClÃnica
Bronchogenic carcinoma is the leading cause of death due to cancer worldwide. Nearly 75% of patients have a disseminated carcinoma at diagnosis. Up to 50% of patients with a localized disease will develop metastasis. Nevertheless, the current scientific evidence has demonstrated that when the metastatic disease is limited, particularly in specific locations such as the brain and the adrenal glands, a multidisciplinary approach with radical intent could achieve a longer survival. READ MORE
| Promoted by |
|
|
|
 |
Acta Oncologica
The purpose of this study was to evaluate the rate and dose response of brachial plexus toxicity post stereotactic body radiation therapy (SBRT) of apically situated lung lesions. Researches retrospectively identified all patients with apically located tumors, defined by the epicenter of the tumor being located superiorly to the aortic arch, and treated with SBRT between 2008 and 2013. Patients with a shorter follow-up than six months were excluded. Primary aim was to evaluate radiation-induced brachial plexopathy (RIBP). Dose to the plexus was assessed by a retrospective delineation of the brachial plexus on the CT used for treatment planning. READ MORE |
|
Abdominal Radiology
Survival outcomes of patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) are heterogeneous. Measuring the apparent diffusion coefficient (ADC) using diffusion-weighted imaging (DWI) may improve overall survival prediction. This study aimed to assess the value of measuring the ADC before and after TACE in predicting overall survival. READ MORE
Advances in Therapy
Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer that has seen few therapeutic advances, despite ongoing concerted efforts. Immunotherapy has been an effective option in other carcinogen-related cancers and has shown modest activity in SCLC. Monotherapy with the anti-PD-1 antibody nivolumab in patients with at least two prior lines of therapy was associated with a response rate of 11.9% and a median duration of response of 17.9 months, leading to accelerated approval by the Food and Drug Administration (FDA) as third-line therapy for SCLC. READ MORE |
| Cryotherapy is a minimally invasive treatment primarily for kidney, lung, and prostate cancers as well as a palliative treatment for bone pain. It has been used since the 19th Century(see history below), but advancements continue to be made every year. Read more |
|
|
|
|
Reach Your Prospects Every Week
Thousands of industry professionals subscribe to association news briefs, which allows your company to push messaging directly to their inboxes and take advantage of the association's brand affinity.
Connect with Highly Defined Buyers and Maximize Your Brand Exposure |
|
|
|
|
American Journal of Transplantation
Hepatocellular carcinoma (HCC) has become a leading indication for liver transplantation (LT) in the U.S. over the past two decades, accounting for nearly 25% of all LTs conducted yearly. Access to HCC‐related LT has been accomplished primarily through granting Model for End‐Stage Liver Disease (MELD) exception points, which aim to balance the risk of death and waitlist dropout with post‐LT HCC recurrence. Given the finite number of organs, this increase in HCC‐related LT has come at the expense of patients with end‐stage liver disease. READ MORE |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
